vamorolone
Selected indexed studies
- Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. (JAMA Neurol, 2022) [PMID:36036925]
- Vamorolone: First Approval. (Drugs, 2024) [PMID:38103149]
- Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. (Neurology, 2024) [PMID:38335499]
_Worker-drafted node — pending editorial review._
Connections
vamorolone is a side effect of
Sources
- Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. (2022) pubmed
- Vamorolone: First Approval. (2024) pubmed
- Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. (2024) pubmed
- Vamorolone. (2024) pubmed
- Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A Systematic Review. (2024) pubmed
- Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis. (2023) pubmed
- Vamorolone Versus Traditional Glucocorticoids in Duchenne Muscular Dystrophy: A Review and Meta-Analysis of Efficacy and Safety. (2025) pubmed
- Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. (2022) pubmed
- Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy. (2025) pubmed
- Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials. (2025) pubmed